Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-10-13

Clinical Trial Update: RDEA3170 Bioavailability Study [Phase 1]

View source ↗

Summary

The update notes completion and results posting of a Phase 1 bioavailability study of RDEA3170 for gout.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • RDEA3170 (RDEA3170)

Snippet

Sponsor: Ardea Biosciences, Inc. | Conditions: Gout | Phase 1 | Status: COMPLETED | Results posted: 2017-10-13